Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn
OtherArticle

Stereoselective metabolism of bupropion to active metabolites in cellular fractions of human liver and intestine.

Nadia O. Bamfo, Jessica Bo Li Lu and Zeruesenay Desta
Drug Metabolism and Disposition May 5, 2022, DMD-AR-2022-000867; DOI: https://doi.org/10.1124/dmd.122.000867
Nadia O. Bamfo
1Division of Clinical Pharmacology, Indiana University School of Medicine, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jessica Bo Li Lu
1Division of Clinical Pharmacology, Indiana University School of Medicine, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zeruesenay Desta
2Medicine/Division of Clinical Pharmacology, Indiana University School of Medicine, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: zdesta@iu.edu
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Striking stereoselective disposition of the antidepressant and smoking cessation aid bupropion and its active metabolites observed clinically influence patients' response to BUP therapy and its clinically important drug-drug interactions (DDI) with CYP2D6 substrates. However, understanding of the biochemical mechanisms responsible is incomplete. This study comprehensively examined hepatic and extrahepatic stereoselective metabolism of BUP in vitro. Racemic-, R- and S-BUP was incubated separately with pooled cellular fractions of human liver (microsomes, HLMs; S9 fractions, HLS9 fractions; and cytosols, HLCs) and intestinal (microsomes, HIMs; S9 fractions, HIS9 fractions; and cytosols, HICs) and cofactors. Formation of diastereomers of 4-hydroxyBUP (OHBUP), threohydroBUP (THBUP) and erythrohydroBUP (EHBUP) were quantified using a novel chiral UHPLC/MS/MS method. Racemic BUP (but not R- or S-BUP) was found suitable to determine stereoselective metabolism of BUP; both enantiomers showed complete racemization. Compared to that of RR-THBUP, the in vitro intrinsic clearance (Clint) for the formation of SS-THBUP was 42-, 19-, and 8.3-fold higher in HLMs, HLS9 fractions and HLCs, respectively; Clint for the formation of SS-OHBUP and RS-EHBUP were also higher (2.7- to 3.9-fold) than their R-derived counterparts. In cellular fractions of human intestine, {greater than or equal to}95% of total reduction was accounted by the formation of RR-THBUP. Ours is the first to demonstrate marked stereoselective reduction of BUP in HLCs, HIMs, HIS9 fractions and HICs, providing the first evidence for tissue- and cellular fraction-dependent stereoselective metabolism of BUP. These data may serve as the first critical step towards understanding factors dictating BUP's stereoselective disposition, effects and DDI risks.

Significance Statement This work provides a deeper insight into bupropion stereoselective oxidation and reduction to active metabolites in cellular fractions of human liver and intestine tissue. The results demonstrate tissue- and cellular fraction-dependent stereospecific metabolism of bupropion. These data may improve prediction of bupropion stereoselective disposition and understanding of bupropion’s effects and CYP2D6- dependent drug-drug interaction in vivo.

  • drug clearance
  • drug metabolism
  • extrahepatic drug metabolism
  • hepatic elimination
  • metabolite disposition
  • Copyright © 2020 American Society for Pharmacology and Experimental Therapeutics
Next
Back to top

In this issue

Drug Metabolism and Disposition: 51 (2)
Drug Metabolism and Disposition
Vol. 51, Issue 2
1 Feb 2023
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Stereoselective metabolism of bupropion to active metabolites in cellular fractions of human liver and intestine.
(Your Name) has forwarded a page to you from Drug Metabolism & Disposition
(Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
OtherArticle

Stereospecific metabolism of bupropion in vitro.

Nadia O. Bamfo, Jessica Bo Li Lu and Zeruesenay Desta
Drug Metabolism and Disposition May 5, 2022, DMD-AR-2022-000867; DOI: https://doi.org/10.1124/dmd.122.000867

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
OtherArticle

Stereospecific metabolism of bupropion in vitro.

Nadia O. Bamfo, Jessica Bo Li Lu and Zeruesenay Desta
Drug Metabolism and Disposition May 5, 2022, DMD-AR-2022-000867; DOI: https://doi.org/10.1124/dmd.122.000867
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Series-Compartment Models of Hepatic Elimination
  • Warfarin PBPK Model with TMDD Mechanism
  • Identification of payload-containing catabolites of ADCs
Show more Article

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics